MAPT and Alzheimer disease: These findings imply that using existing cutoff values for CSF biomarker levels or ratios involving tau derived from largely Caucasian populations may lack sensitivity in identifying AD in minority populations, and it is not known if cerebral tau imaging can overcome this.